Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Valneva's Chikungunya Shot Shows Strong, Long-Lasting Antibody Persistence At Three Years, Comparable In Older And Younger Adults

On Tuesday, Valneva SE (NASDAQ:VALN) revealed antibody persistence data three years after vaccination with a single dose of its chikungunya vaccine IXCHIQ.

The results align with Valneva’s expectations for this vaccine, confirming a strong and long-lasting antibody persistence across all age groups investigated.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.